New 3D printing materials expand options for manufacturing and prototyping.

  • Inkbit elastomers enhance 3D printing capabilities.
  • Now available through Stratasys Direct.
  • New options for manufacturing and prototyping.

The innovative Inkbit elastomers are now accessible for customers through Stratasys Direct, expanding their versatile offerings in 3D printing materials. These elastomers are designed to meet diverse needs in manufacturing and prototyping, allowing users to explore new possibilities for their projects. This partnership aims to streamline production processes with advanced materials.

The introduction of Inkbit elastomers into Stratasys Direct's catalog includes a range of options suitable for various applications. These materials are engineered to be durable and flexible, catering to industries that require high-performance components. By integrating these elastomers, businesses can benefit from enhanced product development and quicker turnaround times.

Inkbit's collaboration with Stratasys Direct reflects a growing trend in 3D printing technology, aimed at improving material availability and performance. As more companies seek advanced 3D printing solutions, this partnership is poised to fill an essential gap in the market, providing innovative materials to support diverse manufacturing needs.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Pharmacelera Raises $6M to Expand in US and Enhance Drug Discovery Platform

Funding will support growth and technological advancements in drug discovery. Pharmacelera has…

Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering

Generate Biomedicines sets IPO pricing as public offering progresses. Generate Biomedicines announces…

Barr Brands Celebrates 80 Years in Business and 30 Years of Employee Ownership

Memphis company marks long-standing commitment with its workforce Barr Brands marks 80…

WuXi Biologics and Vertex Enter Research Agreement for T-Cell Engager

Collaboration focuses on advancing T-cell engager therapies for cancer treatment WuXi Biologics…